Can a cancer drug stop myeloma before it starts?
NCT ID NCT03236428
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing the drug daratumumab in 42 people with high-risk MGUS or low-risk smoldering multiple myeloma—early, pre-cancerous conditions that can lead to multiple myeloma. The goal is to see if daratumumab can produce a deep response (very good partial response or better) after 20 cycles of treatment. Participants receive the drug intravenously, and the study tracks how well it controls the abnormal plasma cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Daratumumab (Darzalex)
- What this could lead to
- If successful, this could show that daratumumab can significantly reduce or eliminate abnormal plasma cells, potentially delaying or preventing progression to active multiple myeloma.
- What could go wrong
- This is a small, early-phase study (42 participants) without a control group, so results may not be definitive. Daratumumab can cause infusion reactions and increase infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Karmanos Cancer Insitute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
Pacific Cancer Care
Monterey, California, 93940, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a multiple myeloma drug shield the kidneys in MGRS?
- Could a new immunotherapy stop smoldering myeloma before it becomes active cancer?
- New scan spots hidden organ damage before symptoms start
- New blood test screening targets hidden cancer in black communities
- Gut bacteria drug shows promise against blood disorder
- New antibody shows promise in slowing early myeloma